94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Allergy
Sec. Rhinology
Volume 6 - 2025 | doi: 10.3389/falgy.2025.1579224
This article is part of the Research Topic Strategic Selection of Biologic Therapies in CRSwNP Management View all articles
Biologic therapies and CRSwNP How does asthma coexistence affect the Strategic Selection of Biologic Therapies in CRSwNP Management?
Provisionally accepted- 1 Private Türkiye Hospital, Department of Pulmonology, Istanbul, Türkiye
- 2 Faculty of Medicine, Department of Otorhinolaryngology, Kırıkkale University, Kırıkkale, Türkiye
- 3 Yazir Private Otorhinolaryngology Clinic, Izmir, Türkiye
- 4 Faculty of Medicine, Department of Otorhinolaryngology, Eskişehir Osmangazi University, Eskişehir, Eskişehir, Türkiye
Objectives: We reviewed asthma coexistence and the selection of biologic therapies in CRSwNP Management.Methods: The literature review utilized Google and Google Scholar, in addition to PubMed, EBSCO, and Proquest Central at Kırıkkale University. We searched for " CRSwNP “, "asthma”, “biologic therapies”, “Anti-IL-4RA”, “Dupilumab”, “Anti-IgE”, “Omalizumab”, “Anti-IL-5”, “mepolizumab” from 2024 to 2000.Results: Patients with CRSwNP frequently have co-occurring lower airway illnesses, including asthma and AERD asthma, which have a shared pathogenesis. The inflammatory bases of CRSwNP and asthma might be heterogeneous, with a type 2 or, less frequently, a non-type two inflammatory history. Lower airway inflammation and asthma control are worse in patients with asthma who also have CRSwNP. Patients with CRSwNP can now access targeted biologic medicines, a novel therapy option. The US Food and Drug Administration (FDA) has authorized three medications for CRSwNP: dupilumab, omalizumab, and mepolizumab. To treat chronic rhinosinusitis with a biological agent, the 2020 European position paper on rhinosinusitis established clear indications. A patient is considered a biologic therapy candidate if they have either undergone FESS before or did not meet FESS criteria but met three of the five. A diagnosis of concomitant asthma, necessitating an inhaled glucocorticoid controller regularly, is one of the five requirements.Conclusion: Biologic treatments have the potential to be used in certain patients where CRSwNP and asthma coexist. The recommended treatments include omalizumab, dupilumab, and mepolizumab.
Keywords: CRSwNP, asthma coexistence, Biologic therapies, Dupilumab, Omalizumab, Mepolizumab
Received: 18 Feb 2025; Accepted: 19 Mar 2025.
Copyright: © 2025 Ozdemir, BAYAR MULUK, Yazır and Cingi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
NURAY BAYAR MULUK, Faculty of Medicine, Department of Otorhinolaryngology, Kırıkkale University, Kırıkkale, Türkiye
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.